Posted in FDA PDUFA on Jul 27th, 2010
Remember Isotechnika? ISA.TO (or IPHAF) is the company whose FDA Advisory Panel was cancelled with only a few days notice. The explanation the company gave was vauge at best. However, the company claims the Priority Review PDUFA date of 8/3/10 for Voclosporin is still valid, and they expect to hear from the FDA by that [...]
Posted in Breakout on Jun 21st, 2010
Today ISA.TO (IPHAF) hit a 52 week hight at $.43, trading at over 8x its average daily volume. On June 3rd I published an article on ISA.TO (see link here) when the price was at $.27, recommending a buy before the run-up began. Today’s peak represented a 60% gain in price and we still have [...]
Posted in Watchlist on Jun 20th, 2010
ISA.TO (IPHAF) – #1 on the Watchlist this week is Isotechnika Pharma. On Monday of next week (June 28th) they have an FDA Advisory Panel for their main drug, Voclosporin. A reminder to those who are new to trading FDA Panel catalysts, the FDA releases the official “notes” to the meeting a few days ahead [...]
Posted in FDA Panel, Run-Up Method on Jun 17th, 2010
ISA.TO (IPHAF) is up over 30% in the last week and is trading on triple the normal volume. Hopefully this trend of daily 7% gains continues through next week. Just a reminder- we have a little more than a week to go before the FDA Panel on June 28th. The notes for the meeting that include [...]
Posted in FDA, FDA Panel, Run-Up Method on May 11th, 2010
Isotechnika just released the following news: EDMONTON, May 11 /CNW/ – Isotechnika Pharma Inc. today announced that the Dermatology and Ophthalmology Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review partner, Lux Biosciences’, New Drug Application (NDA) for voclosporin on June 28, 2010. Voclosporin is proposed for the treatment [...]
Twitter
Facebook
RSS
Email